Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
Ziye ZhouChenxiang WangLili YingMi JinFangfang ZhangDa-Wei ShiPublished in: Journal of clinical pharmacy and therapeutics (2021)
By mining the adverse event report signals in the FAERS database, we found the exposure event signals of AIHFEs in ALK TKIs were "hepatic failure," "hepatitis fulminant" and "hepatic necrosis". AIHFEs were more likely to appear in the reports of ceritinib, crizotinib and alectinib.
Keyphrases
- adverse drug
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- advanced non small cell lung cancer
- peritoneal dialysis
- high glucose
- drug induced
- emergency department
- prognostic factors
- electronic health record
- diffuse large b cell lymphoma
- patient reported outcomes
- diabetic rats
- tyrosine kinase
- protein kinase
- endothelial cells